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Sarcoidosis Mimicking Multiple Myeloma
Gabriela Firak DO and Sehris Khawaja DO
Lehigh Valley Health Network, Allentown, Pennsylvania

BACKGROUND
•	Sarcoidosis is a systemic disease of unknown
etiology characterized by non-caseating
granuloma formation affecting primarily
4
young individuals aged 20-39.
•	In over 90 percent of the cases sarcoidosis
targets the lungs or the related lymph nodes
4
but it can affect any organ system.

Table 1. Manifestations of Sarcoidosis
Pulmonary
Cardiac
Cutaneous
Neurological
Ocular
Osseous
Hypercalemia

>90%

CASE PRESENTATION
•	A 70-year-old Caucasian female presented to the emergency department with symptoms of confusion and low back
pain. She was found to have an elevated calcium level of 14 mg/dL, creatinine of 3.8 mg/dL with a baseline of 1.3
mg/dL, and a hemoglobin of 10 g/dL with a baseline of 12 g/dL.
•	X-ray imaging of the lumbar spine was concerning for a compression fracture with osteolytic changes.
•	She was treated with intravenous hydration and calcitonin with correction of her renal and electrolyte abnormalities.
•	Her presentation raised concern for multiple myeloma and work up was initiated.
•	Surprisingly, the bone marrow biopsy demonstrated granulomatous inflammation.
•	In addition, laboratory data revealed SPEP/UPEP negative for monoclonal gammopathy, as well as elevated
1,25-dihydroxyvitamin D and angiotensin converting enzyme (ACE) levels.
•	A skeletal survey was performed for completion and was unremarkable for additional bony abnormalities.
•	Additional laboratory data performed in context of hypercalcemia work up was also unrevealing as seen in Table 2.
•	Inconsistent with the diagnosis, CT of the chest was negative for parenchymal or lymph node involvement of the
pulmonary system.
•	Patient also displayed potential cardiac manifestations of her disease given history of conduction abnormalities
requiring a pacemaker as well as a diagnosis of diastolic dysfunction.
•	This information supported the diagnosis of sarcoidosis.

5%
10-60%
3-13%
10-20%

Renal

35-50%

Gastrointestinal/Hepatic

50-80%

Parathyroid Hormone

6.2 pg/mL

Parathyroid Related Peptide

3.4 pml/L

Angiotensin Converting Enzyme

•	Isolated extrapulmonary manifestations of sarcoidosis are rare and present in less
1
than 10 percent of reported cases.
•	Bone marrow involvement has only been described in less than 5 percent of
3
cases.
•	This is potentially due to a low number of bone biopsies performed and could
3
underrepresent the true incidence of bone marrow sarcoidosis.
•	Sarcoid can present as sclerotic or lytic lesions on radiographic data.

6

•	Hematologic abnormalities can be seen in up to 30 percent of cases.

5

•	Steroids are first line therapy for any manifestation of sarcoidosis.

2

•	While there is a broad differential for granulomatous lesions the clinical picture of
the patient presented is less likely a result of other infectious, vasculitic, neoplastic,
or chemical/environmental etiologies.
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Figure 1. CT chest without
evidence of pulmonary sarcoidosis

Figure 2. Granulomatous
Inflammation

FOLLOW-UP
•	Patient was discharged on a year long steroid taper without recurrence of hypercalcemia during the course of the
year.
•	Her hemoglobin increased from 10 g/dL on initial presentation to her baseline of 12 g/dL.
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